BMY-14802

BMY-14802

Clinical data
Other names	BMS-181100; MJ-14802
ATC code	None
Identifiers
IUPAC name 1-(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]butan-1-ol
CAS Number	105565-56-8 N
PubChem CID	108046
IUPHAR/BPS	8
ChemSpider	97151 N
UNII	A5NB5G07JO
ChEMBL	ChEMBL60859 N
CompTox Dashboard (EPA)	DTXSID70909596
Chemical and physical data
Formula	C18H22F2N4O
Molar mass	348.398 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1cc(F)ccc1C(O)CCCN2CCN(CC2)c3ncc(F)cn3
InChI InChI=1S/C18H22F2N4O/c19-15-5-3-14(4-6-15)17(25)2-1-7-23-8-10-24(11-9-23)18-21-12-16(20)13-22-18/h3-6,12-13,17,25H,1-2,7-11H2 N Key:ZXUYYZPJUGQHLQ-UHFFFAOYSA-N N
NY (what is this?)  (verify)

BMY-14802, also known as BMS-181100, is a drug with antipsychotic effects which acts as both a sigma receptor antagonist and a 5-HT_1A receptor agonist. It also has affinity for the 5-HT₂ and D₄ receptors. The drug reached phase III clinical trials for the treatment of psychosis but was never marketed.

See also

• Enciprazine
• Ensaculin
• Mafoprazine
• Azaperone
• Fluanisone